The Goldman Sachs Group Begins Coverage on Insulet (NASDAQ:PODD)
The Goldman Sachs Group began coverage on shares of Insulet (NASDAQ:PODD – Get Free Report) in a research report issued on Friday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $380.00 price target on the medical instruments supplier’s stock. The Goldman Sachs Group’s price target indicates a potential upside of 17.10% from […]
The Goldman Sachs Group began coverage on shares of Insulet (NASDAQ:PODD – Get Free Report) in a research report issued on Friday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $380.00 price target on the medical instruments supplier’s stock. The Goldman Sachs Group’s price target indicates a potential upside of 17.10% from […]
